Language:

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-09, Vol.383 (10), p.944-957 [Peer Reviewed Journal]

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2002787

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
Author: Wolf, Jürgen ; Seto, Takashi ; Han, Ji-Youn ; Reguart, Noemi ; Garon, Edward B ; Groen, Harry J.M ; Tan, Daniel S.W ; Hida, Toyoaki ; de Jonge, Maja ; Orlov, Sergey V ; Smit, Egbert F ; Souquet, Pierre-Jean ; Vansteenkiste, Johan ; Hochmair, Maximilian ; Felip, Enriqueta ; Nishio, Makoto ; Thomas, Michael ; Ohashi, Kadoaki ; Toyozawa, Ryo ; Overbeck, Tobias R ; de Marinis, Filippo ; Kim, Tae-Min ; Laack, Eckart ; Robeva, Anna ; Le Mouhaer, Sylvie ; Waldron-Lynch, Maeve ; Sankaran, Banu ; Balbin, O. Alejandro ; Cui, Xiaoming ; Giovannini, Monica ; Akimov, Mikhail ; Heist, Rebecca S
Subjects: Antimitotic agents ; Antineoplastic agents ; Antitumor activity ; Biomarkers ; Confidence intervals ; Copy number ; Edema ; Enrollments ; Gene amplification ; Hypotheses ; Kinases ; Lung cancer ; Lung cancer, Non-small cell ; Medical prognosis ; Metastasis ; Mutation ; Nausea ; Non-small cell lung carcinoma ; Patient outcomes ; Pharmacokinetics ; Small cell lung carcinoma ; Statistical analysis ; Tumors
Is Part Of: The New England journal of medicine, 2020-09, Vol.383 (10), p.944-957
Description: MET is altered by skipping exon 14 or gene amplification in 1 to 2% of patients with non–small-cell lung cancer. Capmatinib, a MET -specific tyrosine kinase inhibitor, led to a response in 40% of previously treated patients and in 67% of previously untreated patients whose tumors had MET alterations, with a median response duration of 9 months and 12 months, respectively.
Publisher: Boston: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa2002787
Source: ProQuest One Psychology
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2002787

Searching Remote Databases, Please Wait